• Lexicon Pharmaceuticals posted revenue of $21.1 million for first-quarter 2026, swinging from $1.3 million a year earlier as $20 million of Novo Nordisk development milestones supplemented $1.1 million of INPEFA net sales.
• Net loss narrowed to $1 million, or less than $0.01 per share, from a loss of $25.3 million, or $0.07 per share, a year earlier.
• R&D expense fell to $12.8 million from $15.3 million, due to completion of PROGRESS Phase 2b and licensing of LX9851; SG&A dropped to $9.2 million from $11.6 million on reduced INPEFA marketing and lower personnel costs.
• Cash, investments and restricted cash climbed to $199.7 million at March 31 from $125.2 million at Dec. 31, reflecting $96.5 million of net proceeds from February stock sales.
• SONATA-HCM expected to complete enrollment mid-2026 with topline results in first-quarter 2027; ZYNQUISTA NDA resubmission anticipated mid-2026 with potential approval in 2026, while Novo Nordisk began Phase 1 testing of LX9851 with completion expected first-quarter 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001062822-26-000098), on May 07, 2026, and is solely responsible for the information contained therein.